Journey Medical (DERM) Stock: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$7.86
-0.04 (-0.51%)
▼
5d:
+5.22%
30d:
+20.37%
90d:
+31.66%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DERM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DERM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.85
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.84
20.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $7.86, which is considered extended relative to its 30-day fair value range of $6.42 to $7.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.6) compared to its historical average (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 11.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a strong uptrend. Immediate support is located at $7.25, while resistance sits at $8.15.
Market Sentiment: DERM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+74.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DERM is in a strong uptrend. Immediate support is located at $7.25, while resistance sits at $8.15.
Market Sentiment: DERM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+74.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.42 -
$7.60
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.9% below Wall St target ($13.75)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.42 -
$7.60
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.78
(9.9%)
Support & Resistance Levels
Support Level
$7.25
Resistance Level
$8.15
Current Trend
Strong Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.60
Wall Street Target
$13.75
(+74.9%)
Revenue Growth (YoY)
23.3%
Profit Margin
-8.9%
Valuation Discount vs History
-11.4% cheaper
PE vs Historical
11.6 vs 16.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.4%
(market-implied from PE analysis)
1-Year Target
$7.07
(-10%)
2-Year Target
$6.37
(-19%)
3-Year Target
$5.73
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→17)
$8.25
(+5%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.6 to 16.7
Stabilization Target:
$11.31
(+43.9%)
PE Expansion Potential:
+43.9%
Share & Embed Analysis
Last updated: September 07, 2026 3:39 AM ET
Data refreshes hourly during market hours. Next update: 4:39 AM
Data refreshes hourly during market hours. Next update: 4:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 61 BUY |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 77 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 41 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 44 HOLD |
